Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer

Table 1 Patient characteristics according to BRAF or KRAS status n (%)

Characteristics	KRAS status			BRAF status
	Wild-type n = 500	Mutant n = 312	P value	Wild-type n = 771	Mutant n = 40	P value
Age (yr)			0.11			0.40
mean ± SD	63.5 ± 10.3	64.7 ± 10.3		63.9 ± 10.3	65.4 ± 11.6
Gender			0.02			0.006
Male	308 (62)	166 (53)		459 (60)	15 (38)
Female	192 (38)	146 (47)		312 (40)	25 (63)
Tumor location			0.37			< 0.001
Proximal	134 (27)	98 (31)		201 (26)	31 (78)
Distal	213 (43)	125 (40)		332 (43)	5 (13)
Rectum	153 (31)	89 (29)		238 (31)	4 (10)
Histological grade			0.24			< 0.001
Well/moderate	472 (94)	288 (92)		728 (94)	31 (78)
Poor/mucinous	28 (6)	24 (8)		43 (6)	9 (23)
T stage			0.12			0.89
1	52 (10)	31 (10)		79 (10)	4 (10)
2	106 (21)	46 (15)		145 (19)	7 (18)
3	286 (57)	200 (64)		462 (60)	23 (58)
4	56 (11)	35 (11)		85 (11)	6 (15)
LN metastasis			0.18			0.96
Yes	180 (36)	127 (41)		292 (38)	15 (38)
No	320 (64)	185 (59)		479 (62)	25 (63)
TNM stage			0.09			0.92
I	125 (25)	58 (19)		173 (22)	10 (25)
II	195 (39)	127 (41)		306 (40)	15 (38)
III	180 (36)	127 (41)		292 (38)	15 (38)
Adjuvant chemotherapy			0.44			0.57
Yes	217 (43)	144 (46)		344 (45)	16 (40)
No	283 (57)	168 (54)		427 (55)	24 (60)
MSI status			0.33			< 0.001
MSS/MSI-L	455 (91)	290 (93)		728 (94)	16 (40)
MSI-H	45 (9)	22 (7)		43 (6)	24 (60)

SD: Standard deviation; LN: Lymph node; TNM: Tumor-Node-Metastasis; MSI: Microsatellite instability; MSS: Microsatellite stable; MSI-L: Microsatellite instability-low; MSI-H: Microsatellite instability-high.